

Transcript of Timothy Buss

Date: February 8, 2018 Case: Pfizer, Inc. -v- Genentech, Inc. (PTAB)

Planet Depos Phone: 888.433.3767 Email:: transcripts@planetdepos.com www.planetdepos.com

 \mathbf{O}

R

M

Δ

WORLDWIDE COURT REPORTING | INTERPRETATION | TRIAL SERVICES

Find authenticated court documents without watermarks at docketalarm.com.

Transcript of Timothy Buss Conducted on February 8, 2018

1	1 UNITED STATES PATENT AND TRADEMARK OFFICE	1	3 APPEARANCES
2 3	BEFORE THE PATENT TRIAL AND APPEAL BOARD		FOR PATENT OWNER GENENTECH, INC.:
4			WILMERHALE
5	PFIZER, INC.,		BY: ROBERT GUNTHER, ESQUIRE
6	Petitioner,	6	7 World Trade Center
7	٧.		250 Greenwich Street
8	GENENTECH, INC.,		New York, New York 10007
9	Patent Owner.	9	212.230.8800
10		10	robert.gunther@wilmerhale.com
11	Case IPR2017-01488	11	
12	Case IPR2017-01489	12	FOR PATENT OWNER GENENTECH, INC.:
13	Patent 6,407,213	13	WILMERHALE
14		14	BY: ANDREW H. LE, ESQUIRE
15		15	950 Page Mill Road
16	VIDEO DEPOSITION OF TIMOTHY BUSS	16	Palo Alto, California 94304
17	FEBRUARY 8, 2018	17	650.858.6010
18	Reported by: Margaret A. Smith, CSR #9733, RPR, CRR	18	andrew.le@wilmerhale.com
19		19	
20		20	
21		21	
22		22	
23		23	
24		24	
25		25	
	2	-	4
1		1	APPEARANCES (continued):
2	INDEX	2	
3		3	FOR PETITIONER PFIZER, INC., AND THE DEPONENT:
4	EXAMINATION PAGE	4	
5	BY MR. GUNTHER 7, 148		BY: BENJAMIN LASKY, ESQUIRE
6	BY MR. LASKY 138		601 Lexington Avenue
7		7	New York, New York 10022
8	DEPOSITION EXHIBIT:		212.446.6415
9	Exhibit 2056 - Expert Declaration of Edward Ball, 21	9	blasky@kirkland.com
10	M.D. in Support of Petition for Inter	10	
11	Partes Review of Patent No. 6,407,213		FOR PETITIONER PFIZER, INC., AND THE DEPONENT:
	Exhibit 2057 - Document entitled "About HNCs and 30		KIRKLAND & ELLIS LLP
13	HNDs - SQA"		BY: KAREN L. YOUNKINS, ESQUIRE
	HNDS - SQA Exhibit 2058 - Redline document 85		BT: KAKEN L. YUUNKINS, ESQUIKE 333 South Hope Street
14	EXHIBIT 2030 Rediffe document 03		Los Angeles, California 90071
15		110	
15 16		16	
16	(Exhibite 2055 to 2059 are baund espectation under		213.680.8140
16 17	(Exhibits 2056 to 2058 are bound separately under	17	213.680.8140 karen.younkins@kirkland.com
16 17 18	(Exhibits 2056 to 2058 are bound separately under nonconfidential cover)	17 18	karen.younkins@kirkland.com
16 17 18 19	nonconfidential cover)	17 18 19	karen.younkins@kirkland.com THE VIDEOGRAPHER: Christian Teare
16 17 18 19 20	nonconfidential cover) (Previously marked Exhibits 1001, 1004, 1021, 1048, 1504,	17 18 19 20	karen.younkins@kirkland.com
16 17 18 19 20 21	nonconfidential cover) (Previously marked Exhibits 1001, 1004, 1021, 1048, 1504, 1069, and Paper No. 27 were referenced and are bound	17 18 19 20 21	karen.younkins@kirkland.com THE VIDEOGRAPHER: Christian Teare
16 17 18 19 20 21 22	nonconfidential cover) (Previously marked Exhibits 1001, 1004, 1021, 1048, 1504,	17 18 19 20 21 22	karen.younkins@kirkland.com THE VIDEOGRAPHER: Christian Teare
16 17 18 19 20 21 22 23	nonconfidential cover) (Previously marked Exhibits 1001, 1004, 1021, 1048, 1504, 1069, and Paper No. 27 were referenced and are bound	17 18 19 20 21 22 23	karen.younkins@kirkland.com THE VIDEOGRAPHER: Christian Teare
16 17 18 19 20 21 22 23 24	nonconfidential cover) (Previously marked Exhibits 1001, 1004, 1021, 1048, 1504, 1069, and Paper No. 27 were referenced and are bound	17 18 19 20 21 22 23 24	karen.younkins@kirkland.com THE VIDEOGRAPHER: Christian Teare
16 17 18 19 20 21 22 23	nonconfidential cover) (Previously marked Exhibits 1001, 1004, 1021, 1048, 1504, 1069, and Paper No. 27 were referenced and are bound	17 18 19 20 21 22 23	karen.younkins@kirkland.com THE VIDEOGRAPHER: Christian Teare
16 17 18 19 20 21 22 23 24	nonconfidential cover) (Previously marked Exhibits 1001, 1004, 1021, 1048, 1504, 1069, and Paper No. 27 were referenced and are bound	17 18 19 20 21 22 23 24	karen.younkins@kirkland.com THE VIDEOGRAPHER: Christian Teare

A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Transcript of Timothy Buss Conducted on February 8, 2018

	5		7	
1	VIDEO DEPOSITION OF TIMOTHY BUSS, taken on behalf	1	firm.	
2	of The Patent Owner, at 2137 Pacific Highway, San Diego,	2		
3	California, commencing on Thursday, February 8, 2018, at	3	TIMOTHY BUSS,	
4	8:49 a.m., before Margaret A. Smith, Certified Shorthand	4	having been first duly sworn, was examined and testified	
5	Reporter, CSR No. 9733, RPR, CRR.	5	as follows:	
6		6		
7		7	EXAMINATION	
8		8	BY MR. GUNTHER:	
9		9	Q Good morning, Mr. Buss.	
10		10	A Good morning.	
11		11	Q Have you been deposed before?	
12		12	A No.	
13		13	Q Okay. So this is your first time?	
14		14	A It is my first time.	
15		15	Q Okay. And have you ever acted as an ex	
16		16	expert witness in a litigation matter prior to today?	
17		17	A No.	
18		18	Q Okay. Now, I'd like to ask you when you were	
19		19	first retained for this matter.	
20		20	A I don't recall precisely, but it would have	
21		21	been at least a year ago	
22		22	Q Okay.	
23		23	A possibly more.	
24		24	Q All right. And when you were retained, who	
25		25	were you retained by?	
	6		8	3
1	San Diego, California; February 8, 2018; 8:49 a.m.	1	A I was contacted by Kirkland and Ellis.	
2		2	Q Okay. And is your agreement with Kirkland and	
3	VIDEOGRAPHER: Good morning. We are on the	3	Ellis, or with Pfizer?	
4	record. This is the videotaped deposition of Timothy		,	
5	record. This is the videotaped deposition of fimothy	4	A With Kirkland and Ellis.	
	Buss, taken in the matter of Hospira, Inc., versus	4		
6		4 5	Q Okay. And and who first contacted you in	
6 7	Buss, taken in the matter of Hospira, Inc., versus	4 5 6	Q Okay. And and who first contacted you in terms of your retention in this matter?	
	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case	4 5 6 7	Q Okay. And and who first contacted you in terms of your retention in this matter?A You know, I can't recall. It might have been	
7	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89.	4 5 6 7 8	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. 	
7 8	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018,	4 5 6 7 8 9	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. 	
7 8 9	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m.	4 5 6 7 8 9 10	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A I spoke with several different people at 	
7 8 9 10	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video	4 5 6 7 8 9 10 11	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A I spoke with several different people at Kirkland and Ellis. 	
7 8 9 10 11	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos.	4 5 6 7 8 9 10 11 12	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A I spoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest 	
7 8 9 10 11 12	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the	4 5 6 7 8 9 10 11 12 13	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A Ispoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? 	
7 8 9 10 11 12 13	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the Hilton Garden Inn, 2137, Pacific Highway, in San Diego,	4 5 6 7 8 9 10 11 12 13 14	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A Ispoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? A Not to my knowledge. 	
7 8 9 10 11 12 13 14	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the Hilton Garden Inn, 2137, Pacific Highway, in San Diego, California. The certified shorthand reporter is Maggie	4 5 6 7 8 9 10 11 12 13 14 15	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A Ispoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? A Not to my knowledge. Q Okay. Do you know how it came to be that you 	
7 8 9 10 11 12 13 14 15	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the Hilton Garden Inn, 2137, Pacific Highway, in San Diego, California. The certified shorthand reporter is Maggie Smith with Planet Depos.	4 5 6 7 8 9 10 11 12 13 14 15 16	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A I spoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? A Not to my knowledge. Q Okay. Do you know how it came to be that you became a candidate to be an expert in this matter? 	
7 8 9 10 11 12 13 14 15 16	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the Hilton Garden Inn, 2137, Pacific Highway, in San Diego, California. The certified shorthand reporter is Maggie Smith with Planet Depos. If counsel would please state their	4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A Ispoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? A Not to my knowledge. Q Okay. Do you know how it came to be that you became a candidate to be an expert in this matter? A No, I don't know that. 	
7 8 9 10 11 12 13 14 15 16 17	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the Hilton Garden Inn, 2137, Pacific Highway, in San Diego, California. The certified shorthand reporter is Maggie Smith with Planet Depos. If counsel would please state their appearances, the reporter will swear in the witness.	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A Ispoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? A Not to my knowledge. Q Okay. Do you know how it came to be that you became a candidate to be an expert in this matter? A No, I don't know that. Q Okay. Now, when you were retained, can you 	
7 8 9 10 11 12 13 14 15 16 17 18	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the Hilton Garden Inn, 2137, Pacific Highway, in San Diego, California. The certified shorthand reporter is Maggie Smith with Planet Depos. If counsel would please state their appearances, the reporter will swear in the witness. MR. LASKY: My name is Benjamin Lasky from	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A Ispoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? A Not to my knowledge. Q Okay. Do you know how it came to be that you became a candidate to be an expert in this matter? A No, I don't know that. Q Okay. Now, when you were retained, can you tell me about how well, let me do this. Let me 	
7 8 9 10 11 12 13 14 15 16 17 18 19	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the Hilton Garden Inn, 2137, Pacific Highway, in San Diego, California. The certified shorthand reporter is Maggie Smith with Planet Depos. If counsel would please state their appearances, the reporter will swear in the witness. MR. LASKY: My name is Benjamin Lasky from Kirkland & Ellis for Pfizer, Inc., and the witness. And	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A I spoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? A Not to my knowledge. Q Okay. Do you know how it came to be that you became a candidate to be an expert in this matter? A No, I don't know that. Q Okay. Now, when you were retained, can you tell me about how well, let me do this. Let me I tell me mark your declarations, hand you your 	
7 8 9 10 11 12 13 14 15 16 17 18 19 20	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the Hilton Garden Inn, 2137, Pacific Highway, in San Diego, California. The certified shorthand reporter is Maggie Smith with Planet Depos. If counsel would please state their appearances, the reporter will swear in the witness. MR. LASKY: My name is Benjamin Lasky from Kirkland & Ellis for Pfizer, Inc., and the witness. And just for the record, the petitioner in these IPRs is	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A Ispoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? A Not to my knowledge. Q Okay. Do you know how it came to be that you became a candidate to be an expert in this matter? A No, I don't know that. Q Okay. Now, when you were retained, can you tell me about how well, let me do this. Let me I the mark your declarations, hand you your declarations. They have already been marked. 	
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the Hilton Garden Inn, 2137, Pacific Highway, in San Diego, California. The certified shorthand reporter is Maggie Smith with Planet Depos. If counsel would please state their appearances, the reporter will swear in the witness. MR. LASKY: My name is Benjamin Lasky from Kirkland & Ellis for Pfizer, Inc., and the witness. And just for the record, the petitioner in these IPRs is Pfizer, not Hospira.	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A Ispoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? A Not to my knowledge. Q Okay. Do you know how it came to be that you became a candidate to be an expert in this matter? A No, I don't know that. Q Okay. Now, when you were retained, can you tell me about how well, let me do this. Let me let me mark your declarations, hand you your declarations. They have already been marked. 	
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the Hilton Garden Inn, 2137, Pacific Highway, in San Diego, California. The certified shorthand reporter is Maggie Smith with Planet Depos. If counsel would please state their appearances, the reporter will swear in the witness. MR. LASKY: My name is Benjamin Lasky from Kirkland & Ellis for Pfizer, Inc., and the witness. And just for the record, the petitioner in these IPRs is Pfizer, not Hospira. With me today from Kirkland and Ellis is Karen	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A Ispoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? A Not to my knowledge. Q Okay. Do you know how it came to be that you became a candidate to be an expert in this matter? A No, I don't know that. Q Okay. Now, when you were retained, can you tell me about how well, let me do this. Let me let me mark your declarations, hand you your declarations. They have already been marked. A Thank you. Q So I we're handing you two documents the 	
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the Hilton Garden Inn, 2137, Pacific Highway, in San Diego, California. The certified shorthand reporter is Maggie Smith with Planet Depos. If counsel would please state their appearances, the reporter will swear in the witness. MR. LASKY: My name is Benjamin Lasky from Kirkland & Ellis for Pfizer, Inc., and the witness. And just for the record, the petitioner in these IPRs is Pfizer, not Hospira. With me today from Kirkland and Ellis is Karen Younkins, and from Pfizer, Wendy Hsu, H-s-u. 	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A Ispoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? A Not to my knowledge. Q Okay. Do you know how it came to be that you became a candidate to be an expert in this matter? A No, I don't know that. Q Okay. Now, when you were retained, can you tell me about how well, let me do this. Let me let me mark your declarations, hand you your declarations. They have already been marked. 	
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Buss, taken in the matter of Hospira, Inc., versus Genentech, Inc. It's a U.S. Patent Office case IPR2017-01488 and 89. Today's date is Thursday, February 8th, 2018, and the time is 8:49 a.m. My name is Christian Teare, a legal video specialist, representing Planet Depos. This video deposition is taking place at the Hilton Garden Inn, 2137, Pacific Highway, in San Diego, California. The certified shorthand reporter is Maggie Smith with Planet Depos. If counsel would please state their appearances, the reporter will swear in the witness. MR. LASKY: My name is Benjamin Lasky from Kirkland & Ellis for Pfizer, Inc., and the witness. And just for the record, the petitioner in these IPRs is Pfizer, not Hospira. With me today from Kirkland and Ellis is Karen Younkins, and from Pfizer, Wendy Hsu, H-s-u. MR. GUNTHER: And for the patent owner,	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 Q Okay. And and who first contacted you in terms of your retention in this matter? A You know, I can't recall. It might have been Stefan. Yeah, I don't actually recall. Q Okay. A Ispoke with several different people at Kirkland and Ellis. Q Did to your knowledge, did Dr. Foote suggest that you be an expert in this case? A Not to my knowledge. Q Okay. Do you know how it came to be that you became a candidate to be an expert in this matter? A No, I don't know that. Q Okay. Now, when you were retained, can you tell me about how well, let me do this. Let me let me mark your declarations, hand you your declarations. They have already been marked. A Thank you. Q So I we're handing you two documents the 	

A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

 9 1 with 1488 IPR. 2 And I'd ask you to take a look at that and just 3 confirm for me that that is in fact your declaration in 4 this matter. 5 A Yeah. 6 Q All right. And if you look at the last page, 7 page 40 8 A Yes. 9 Q that's your signature, and it indicates that 10 you you executed the report on May 22nd, 2017. 11 Correct? 12 A Yes. 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A Ihonestly can't recall. 23 Q Okay. And when you were retained, did you learn that 9
 3 confirm for me that that is in fact your declaration in 4 this matter. 5 A Yeah. 6 Q All right. And if you look at the last page, 7 page 40 8 A Yes. 9 Q that's your signature, and it indicates that 10 you you executed the report on May 22nd, 2017. 11 Correct? 12 A Yes. 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 3 the references that are cited in the Ball declaration? 4 A I was. 5 Q Okay. And did you read each one of those 6 A I 7 Q prior just, I'm sorry. 1 and I'm not 8 great at this either. It's one of my faults. I'll try 9 not to step on you if you try not to step on me, okay, 10 in terms of speaking. 11 A Sure. 12 Q So so in terms of the exhibit, the 13 references that are cited in Dr. Ball's declaration, you 14 were given copies of those. Correct? 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017 as the sort of end date, the date that you 19 Q Okay. Now, let me just so we have them both 20 in form to fus mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether
 3 confirm for me that that is in fact your declaration in 4 this matter. 5 A Yeah. 6 Q All right. And if you look at the last page, 7 page 40 8 A Yes. 9 Q that's your signature, and it indicates that 10 you you executed the report on May 22nd, 2017. 11 Correct? 12 A Yes. 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 3 the references that are cited in the Ball declaration? 4 A I was. 5 Q Okay. And did you read each one of those 6 A I 7 Q prior just, I'm sorry. 1 and I'm not 8 great at this either. It's one of my faults. I'll try 9 not to step on you if you try not to step on me, okay, 10 in terms of speaking. 11 A Sure. 12 Q So so in terms of the exhibit, the 13 references that are cited in Dr. Ball's declaration, you 14 were given copies of those. Correct? 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017 as the sort of end date, the date that you 19 Q Okay. Now, let me just so we have them both 20 in form to fus mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether
 4 this matter. 5 A Yeah. 6 Q All right. And if you look at the last page, 7 page 40 8 A Yes. 9 Q that's your signature, and it indicates that 10 you you executed the report on May 22nd, 2017. 11 Correct? 12 A Yes. 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, did you learn that 4 A Iwas. 4 A Iwas. 5 Q Okay. And did you read each one of those 6 A I 7 Q prior just, I'm sorry. I and I'm not 8 great at this either. It's one of my faults. I'll try 9 not to step on you if you try not to step on me, okay, 10 in terms of speaking. 11 A Sure. 12 Q So so in terms of the exhibit, the 13 references that are cited in Dr. Ball's declaration, you 14 were given copies of those. Correct? 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017, you reviewed those. Correct? 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 that was also executed on May 22, 2017.
 5 A Yeah. 6 Q All right. And if you look at the last page, 7 page 40 8 A Yes. 9 Q that's your signature, and it indicates that 10 you you executed the report on May 22nd, 2017. 11 Correct? 12 A Yes. 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with you declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, did you learn that 5 Q Okay. And did you read each one of those 6 A I 7 Q prior just, I'm sorry. I and I'm not 8 great at this either. It's one of my faults. I'll try 9 not to step on you if you try not to step on me, okay, 10 in terms of speaking. 11 A Sure. 12 Q So so in terms of the exhibit, the 13 references that are cited in Dr. Ball's declaration, you 14 were given copies of those. Correct? 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017, so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 When you were retained, did you learn that
 6 Q All right. And if you look at the last page, 7 page 40 8 A Yes. 9 Q that's your signature, and it indicates that 10 you you executed the report on May 22nd, 2017. 11 Correct? 12 A Yes. 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A Ihonestly can't recall. 23 Q Okay. And when you were retained, did you learn that 6 A I 7 Q prior just, I'm sorry. I and I'm not 8 great at this either. It's one of my faults. I'll try 9 not to step on you if you try not to step on me, okay, 10 in terms of speaking. 11 A Sure. 12 Q So so in terms of the exhibit, the 13 references that are cited in Dr. Ball's declaration, you 14 were given copies of those. Correct? 15 A Iwas. 16 Q And prior to signing your declaration on 17 May 22, 2017 as the sort of end date, the date that you 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 before that you were retained. 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 When you were retained, did you learn that
 7 page 40 8 A Yes. 9 Q that's your signature, and it indicates that 10 you you executed the report on May 22nd, 2017. 11 Correct? 12 A Yes. 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 7 Q - prior just, I'm sorry. I and I'm not 8 great at this either. It's one of my faults. I'll try 9 not to step on you if you try not to step on me, okay, 10 in terms of speaking. 11 A Sure. 12 Q So so in terms of the exhibit, the 13 references that are cited in Dr. Ball's declaration, you 14 were given copies of those. Correct? 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017, you reviewed those. Correct? 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 When you were retained, did you learn that
 8 A Yes. 9 Q that's your signature, and it indicates that 10 you you executed the report on May 22nd, 2017. 11 Correct? 12 A Yes. 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, did you learn that 25 When you were retained, did you learn that 8 great at this either. It's one of my faults. I'll try 9 not to step on you if you try not to step on me, okay, 10 in terms of speaking. 11 A Sure. 12 Q So so in terms of the exhibit, the 13 references that are cited in Dr. Ball's declaration, you 14 were given copies of those. Correct? 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017, you reviewed those. Correct? 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 before that you were retained. 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 that was also executed on May 22, 2017.
 9 Q that's your signature, and it indicates that 10 you you executed the report on May 22nd, 2017. 11 Correct? 12 A Yes. 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A Ihonestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 9 not to step on you if you try not to step on me, okay, 10 in terms of speaking. 11 A Sure. 12 Q So so in terms of the exhibit, the 13 references that are cited in Dr. Ball's declaration, you 14 were given copies of those. Correct? 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017, you reviewed those. Correct? 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 that was also executed on May 22, 2017.
 10 you you executed the report on May 22nd, 2017. 11 Correct? 12 A Yes. 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A Ihonestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 10 in terms of speaking. 11 A Sure. 12 Q So so in terms of the exhibit, the 13 references that are cited in Dr. Ball's declaration, you 14 were given copies of those. Correct? 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017, you reviewed those. Correct? 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 that was also executed on May 22, 2017.
 11 Correct? 12 A Yes. 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 11 A Sure. 12 Q So so in terms of the exhibit, the 13 references that are cited in Dr. Ball's declaration, you 14 were given copies of those. Correct? 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017, you reviewed those. Correct? 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 that was also executed on May 22, 2017.
 12 A Yes. 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 12 Q So so in terms of the exhibit, the 13 references that are cited in Dr. Ball's declaration, you 14 were given copies of those. Correct? 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017, you reviewed those. Correct? 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 is pour declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 that was also executed on May 22, 2017.
 13 Q Okay. Now, as you sit here today, is there 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 13 references that are cited in Dr. Ball's declaration, you 14 were given copies of those. Correct? 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017, you reviewed those. Correct? 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 that was also executed on May 22, 2017.
 14 anything that you'd like to correct or or change in 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 14 were given copies of those. Correct? 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017, you reviewed those. Correct? 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 that was also executed on May 22, 2017.
 15 connection with your declaration? 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 15 A I was. 16 Q And prior to signing your declaration on 17 May 22, 2017, you reviewed those. Correct? 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 When you were retained, did you learn that
 16 A No, there isn't. 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 16 Q And prior to signing your declaration on 17 May 22, 2017, you reviewed those. Correct? 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 that was also executed on May 22, 2017.
 17 Q Okay. Can you tell me approximately using 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 17 May 22, 2017, you reviewed those. Correct? 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 When you were retained, did you learn that
 18 May 22, 2017 as the sort of end date, the date that you 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 18 A Yes. 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 that was also executed on May 22, 2017.
 19 actually signed the declaration. Can you tell me, 20 backing up from there approximately how many months 21 before that you were retained. 22 A I honestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 19 Q Okay. Now, let me just so we have them both 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 that was also executed on May 22, 2017.
 20 backing up from there approximately how many months 21 before that you were retained. 22 A Ihonestly can't recall. 23 Q Okay. And when you were retained, were you 24 informed strike that. 25 When you were retained, did you learn that 20 in front of us mark as exhibit show you what has 20 in front of us mark as exhibit show you what has 21 been previously marked as Pfizer Exhibit 1504. And this 22 is your declaration in the 1489 IPR. And my question 23 is my question, frankly, is whether you can confirm 24 that this is in fact your declaration in the second IPR 25 that was also executed on May 22, 2017.
21 before that you were retained.21 been previously marked as Pfizer Exhibit 1504. And this22 A I honestly can't recall.21 been previously marked as Pfizer Exhibit 1504. And this23 Q Okay. And when you were retained, were you23 is my question, frankly, is whether you can confirm24 informed strike that.24 that this is in fact your declaration in the second IPR25 When you were retained, did you learn that25 that was also executed on May 22, 2017.
22A I honestly can't recall.22 is your declaration in the 1489 IPR. And my question23Q Okay. And when you were retained, were you23 is my question, frankly, is whether you can confirm24 informed strike that.24 that this is in fact your declaration in the second IPR25When you were retained, did you learn that25 that was also executed on May 22, 2017.
23QOkay. And when you were retained, were you23 is my question, frankly, is whether you can confirm24 informed strike that.24 that this is in fact your declaration in the second IPR25When you were retained, did you learn that25 that was also executed on May 22, 2017.
24 informed strike that.24 that this is in fact your declaration in the second IPR25 When you were retained, did you learn that25 that was also executed on May 22, 2017.
25When you were retained, did you learn that25 that was also executed on May 22, 2017.
10 12
1 Mylan had previously filed an IPR preceding against the 1 A Yes.
2 '213 patent? 2 Q Okay. And that's your signature, again, on
3 A Yes, I knew that. 3 page 40 of the declaration
4 Q Okay. And were you provided certain papers 4 A Yes.
5 with respect to the Mylan IPR? 5 Q correct? All right.
6 A I believe what I was presented with with was 6 And is there anything look focusing on
7 the declaration that was submitted by Dr. Ball. 7 Exhibit 1504, is there anything that you would want to
8 Q By Dr. Ball? 8 correct or change with respect to that declaration?
9 A Yeah. 9 A No.
10QOkay. And do you do you recall were you10QOkay. And, sir, in terms of Dr. Ball's
11 giving any other papers from the Mylan IPR? 11 declaration, you utilized some some of the language
12AI do not believe so.12 from that declaration. Correct?
13QOkay. And prior to receiving Dr. Ball's13AI utilized most of the language.
14 declaration, were you asked to to independently form 14 Q Okay. And in your declaration of
15 any opinions with respect to the validity or invalidity 15 paragraph 13 and let's use the the 1004
16 of the '213 patent?16 declaration, just so that you and I are on the on the
17 A No. 17 same document.
18QOkay. So you started your starting point18In paragraph 13, your declaration, you say
19 is it fair to say that your starting point was19 this is about three quarters of the way down the
20 Dr. Ball's declaration?20 paragraph. "Readers of this declaration may note the
21 A Yes.21 language and organization is similar to that of
22 Q Okay. Were you given a Word version of that 22 Dr. Ball's declaration because it did not seem a
23 declaration? 23 necessary expenditure of resources to rewrite the
24 A I believe so.24 material which I independently confirmed as"
25QOkay. And then did you edit it?25 accepting "acceptable and correct." Right?

A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Conducted on F	edituary 8, 2018
13	15
1 A Yes.	1 Q Okay. So it's fair to say you relied entirely
2 Q Okay. All right. And you stand by that	2 in terms of your declaration on on literature that
3 statement. Right?	3 was presented in Dr. Ball's declaration. Correct?
4 A Yes.	4 MR. LASKY: Objection to the form.
5 Q And as a matter of fact well, we'll come	5 BY MR. GUNTHER:
6 back to it. So your your process in terms of the	6 Q You can answer.
7 work that you did in connection with this case is that	7 A Yes.
8 you were after you were retained, you were given	8 Q Okay. Now, you know that Dr. Foote has also
9 Dr. Ball's declaration as a Word document, you were	9 submitted a declaration in these IPR proceedings.
10 given the documents cited in that declaration, you	10 Right?
11 reviewed Dr. Ball's declaration in those documents, and	11 A Yes.
12 wherever you agreed with Dr. Ball, you basically just	12 Q And and you are you know him from
13 left the text as is. Correct?	13 prior to this case. Correct?
14 A Yes. I did adjust the text in places just	14 A Correct.
15 where I thought it could be made a little bit clearer.	15 Q In fact, you were colleagues at in
16 Q Okay.	16 Dr. Winters' lab. Right?
17 A Alittle bit less ambiguous.	17 A Yes.
18 Q Okay. But for the most part so, for	17 A res. 18 Q And you were also colleagues in Dr. Foote's lab
19 example, obviously, in terms of the background section,	19 at Hutchison. Correct?
20 you had to change that because you you're talking	20 A Yes.
21 about your background	
22 A Yes.	
23 Q not his. Right?	23 Q Okay. And how long how many years have you
24 A Yes.	24 actually worked with him as a colleague?
25 Q And in terms of you made some changes. And	25 A Approximately 12.
14	16
1 we'll go we'll talk about this in terms of the person	1 Q Okay. And in fact you list Dr. Foote as a
2 of ordinary skill in the art. Correct?	2 personal reference on your C.V. Correct?
3 A Yes.	3 A Yes.
4 Q But then in terms of the actual substance of	4 Q Do you do you view him as a mentor?
5 the declaration, in terms of the substantive paragraphs	5 A Yes. I've learned a lot while working in his
6 and the references that were cited, most of that, you	6 lab.
7 left unchanged in in terms of Dr. Ball's declaration	7 Q Okay. And do you know whether he had any
8 and used his his language. Correct?	8 anything to do with you being involved in this case?
9 A Correct.	9 MR. LASKY: Objection. Asked and answered.
10 Q Okay. Did you ever talk to Dr. Ball?	10 BY MR. GUNTHER:
11 A No.	11 Q And if I asked that, I apologize, but indulge
12 Q Did you ever ask to talk to Dr. Ball?	12 me on this one. Can you answer it again.
13 A No.	13 A Yeah. I have no knowledge.
14 Q Do you know who he is?	14 Q Okay. Have you spoken to Dr. Foote in
15 A No.	15 connection with your work on this case?
16 Q Okay. Had you ever heard of him	16 A Yes.
17 A No.	17 Q Okay. And tell can you tell me how many
18 Q prior to this case? Okay.	18 times you've spoken with him in connection with your
19 Did you do what attempt to do any diligence	19 work on this case.
20 to determine his reputation in the field?	20 A Once.
21 A No, I didn't.	21 Q All right. When and when was that?
22 Q Have you performed any of your own search of	22 A That was when we were determining the the
23 the literature in connection with any of the work that	23 who would be ordinary ordinary skilled in the art
24 you've done in this matter?	24 Q Okay.
25 A No.	25 A definitions.

A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.